

(19) World Intellectual Property  
Organization  
International Bureau



554036

(43) International Publication Date  
11 November 2004 (11.11.2004)

PCT

(10) International Publication Number  
**WO 2004/096784 A1**

(51) International Patent Classification<sup>7</sup>: **C07D 277/64**,  
417/12, 235/08, 235/10, 277/68, 263/56, A61K 31/4184,  
31/5377, A61P 25/04, 25/28

AstraZeneca R & D Montreal, 7171 Frederick-Banting,  
St. Laurent, Québec H4S 1Z9 (CA). **ZEMRIBO, Ronald**  
[LV/LV]; OSI, Aizkraukles 21, Riga LV 1006 (LV).

(21) International Application Number:  
PCT/SE2004/000635

(74) Agent: **ASTRAZENECA**; Global Intellectual Property,  
S-151 85 Södertälje (SE).

(22) International Filing Date: 26 April 2004 (26.04.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
0301246-5 28 April 2003 (28.04.2003) SE  
0301305-9 5 May 2003 (05.05.2003) SE  
0400044-4 12 January 2004 (12.01.2004) SE

(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(71) Applicant (*for all designated States except US*): **ASTRAZENECA AB** [SE/SE]; S-151 85 Södertälje (SE).

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(72) Inventors; and


(75) Inventors/Applicants (*for US only*): **BESIDSKI**, Yevgeni [SE/SE]; AstraZeneca R & D Södertälje, S-151 85 Södertälje (SE). **BROWN, William** [CA/CA]; AstraZeneca R & D Montreal, 7171 Frederick-Banting, St. Laurent, Québec H4S 1Z9 (CA). **JOHNSTONE, Shawn** [CA/CA]; AstraZeneca R & D Montreal, 7171 Frederick-Banting, St. Laurent, Québec H4S 1Z9 (CA). **LABRECQUE, Denis** [CA/CA]; AstraZeneca R & D Montreal, 7171 Frederick-Banting, St. Laurent, Québec H4S 1Z9 (CA). **MUNRO, Alexander** [CA/CA]; AstraZeneca R & D Montreal, 7171 Frederick-Banting, St. Laurent, Québec H4S 1Z9 (CA). **ROTTICCI, Didier** [FR/SE]; AstraZeneca R & D Södertälje, S-151 85 Södertälje (SE). **WALPOLE, Christopher** [GB/CA];

**Published:**

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

(54) Title: **NEW HETEROCYCLIC AMIDES EXHIBITING AN INHIBITORY ACTIVITY AT THE VANILLOID RECEPTOR 1 (VR1).**



(1)

(57) Abstract: The present invention relates to new compounds of formula I, wherein R<sup>1</sup> to R<sup>8</sup> are as defined as in formula I, or salts, solvates or solvated salts thereof, processes for their preparation and to new intermediates used in the preparation thereof, pharmaceutical compositions containing said compounds and to the use of said compounds in therapy.